Exelixis Posts 28 Percent Spike in Q1 Sales, Expects More Deals in 2001 | GenomeWeb

NEW YORK, May 14 – Comparative genomics company Exelixis of South San Francisco, Calif., said Monday its first quarter revenues increased 28 percent to $7.7 million as milestone payments rose from collaborations with companies including Bayer, Pharmacia, and Bristol Myers Squibb.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.